Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
When autistic kids grow up, Chapter 2: “You need to go to college”
With just a high school equivalency degree and struggling as a single mother, Tempest McDonald is forced to shift her priorities.
When autistic kids grow up, Chapter 2: “You need to go to college”
With just a high school equivalency degree and struggling as a single mother, Tempest McDonald is forced to shift her priorities.
Noncoding RNA sways core autism traits in mice
Small deletions in an X-linked RNA alter social and repetitive behaviors in male mice without broadly affecting learning or memory.
Noncoding RNA sways core autism traits in mice
Small deletions in an X-linked RNA alter social and repetitive behaviors in male mice without broadly affecting learning or memory.
Four protein synthesis pioneers win Kavli Prize in Neuroscience
Their research revealed how neurons synthesize proteins in previously unrecognized places.
Four protein synthesis pioneers win Kavli Prize in Neuroscience
Their research revealed how neurons synthesize proteins in previously unrecognized places.